flanders.bio is the cluster organisation empowering a life sciences driven network economy

flanders.bio is a dynamic, member driven organisation with currently more than 350 members from Belgium and abroad. We help our members to create value by organising Networking and Training Activities, supporting Internationalisation, providing Services and building Expertise. flanders.bio and its members want to be the proud advocates of a reputable global-impact ecosystem in life sciences.

News from flanders.bio and its members

Versterk ons team! flanders.bio zoekt een communicatiemedewerker

Ter ondersteuning van onze activiteiten en ter versterking van ons team zijn wij op zoek naar een COMMUNICATIEMEDEWERKER (m/v).

People | 14 August 17 Read more

Mithra Announces First Subject Completes Estelle® Phase III Study

Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announces that the first European study subject has successfully completed 13 cycles of Estelle® and the end of study physician visit in the E4 Freedom Phase III study program. Estelle® is Mithra’s combined oral contraceptive (COC) candidate, composed of 15 mg Estetrol (E4) and 3 mg Drospirenone (DRSP), and is currently being tested in two Phase III trials in Europe/Russia and in the US/Canada.

Research | 21 August 17 Read more

Scientists unravel role of glutamine synthetase in the spread of cancer

Scientists have discovered an essential mechanism in the spread of cancer. A team led by professor Massimiliano Mazzone (VIB-KU Leuven) and professor Alessandra Castegna (University of Bari) has demonstrated a way to alter the metabolism of macrophages, a particular type of white blood cell often responsible for supporting tumor growth. They found that reducing the glutamine levels of these macrophages changes their behavior: instead of supporting cancer, the macrophages change back into ‘good’ cells and fight the disease. These groundbreaking findings potentially offer new strategies for immunotherapy. The conclusions of the study are published in the leading scientific journal Cell Reports.

Research | 21 August 17 Read more

Ablynx will announce its 2017 half year results with webcast on 24 august 2017

Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] will report its 2017 half year financial results and year-to-date business update on Thursday 24 August 2017 at 7.00 am CET.

Finance | 17 August 17 Read more

argenx to host conference call & webcast to report second quarter business update and half year 2017 financial results

argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced it will host a conference call and audio webcast on Thursday, August 24, 2017 at 3:00 p.m. CEST (9:00 a.m. EDT) to discuss financial results for the first half of 2017 and to provide a second quarter business update.

Finance | 17 August 17 Read more

flanders.bio events, trainings & international missions

Strategic Partners